Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune Checkpoint Blockade.
Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune Checkpoint Blockade.
复制标题
全身免疫炎症指数和中性粒细胞-淋巴细胞比值的变化作为接受免疫检查点阻断治疗的胰腺癌患者的预后生物标志物
DOI：
10.3389/fonc.2021.585271
复制
发表时间：
2021
影响因子：
4.7
通讯作者：
Hu Y
中科院分区：
文献类型：
--
作者：
Shang J;Han X;Zha H;Tao H;Li X;Yuan F;Chen G;Wang L;Ma J;Hu Y
目前胰腺癌（PC）治疗方案的疗效仍不令人满意。近年来，免疫检查点阻断（ICB）治疗在许多恶性肿瘤（包括PC）中显示出有希望的抗肿瘤结果。廉价和容易获得的生物标志物，预测治疗反应和预后是迫切需要的。全身免疫炎症指数（SII）和嗜中性淋巴细胞比率（NLR）是各种肿瘤预后的新兴预测指标。我们的目的是研究基线SII、NLR及其变化在接受ICB治疗的PC患者中的预后意义。我们的回顾性分析包括在中国人民解放军总医院接受ICB治疗的PC患者。所有人口统计学、生物学和临床数据均从病历中提取。两次ICB给药后SII的相对变化定义为ΔSII%，并计算为（2次给药后SII-SII基线）/SII基线，ΔNLR%也是如此。使用Kaplan-Meier曲线比较总生存期（OS）和无进展生存期（PFS）。使用考克斯比例风险回归模型，在单变量和多变量分析中评估基线SII、NLR及其变化的预后意义。本分析共纳入了122例接受ICB治疗的PC患者。基线SII（HR=3.28; 95% CI：1.98-5.27; P=0.03）和ΔNLR%（HR=2.21; 95% CI：1.03-4.74; P=0.04）升高与死亡风险增加显著相关。对于接受ICB联合化疗或放疗作为一线治疗的PC患者，基线SII增加是OS（HR=8.06; 95%CI：1.71-37.86; P=0.01）和PFS（HR=2.84; 95%CI：1.37-10.38; P=0.04）的负预测因子。我们的研究揭示了接受ICB治疗的PC患者的基线SII和NLR变化的预后价值。这些预后生物标志物的临床效用需要在前瞻性研究中进一步研究。
The efficacy of current treatment regimens for pancreatic cancer (PC) remains unsatisfactory. In recent years, immune checkpoint blockade (ICB) therapy has shown promising anti-tumor outcomes in many malignancies, including PC. Inexpensive and readily available biomarkers which predict therapeutic responses and prognosis are in critical need. Systemic immune-inflammation index (SII) and neutrophil-lymphocyte ratio (NLR) are emerging predictors for prognosis of various tumors. We aim to investigate the prognostic significance of baseline SII, NLR, and their changes in PC patients treated with ICB. Our retrospective analysis included PC patients treated with ICB therapy in the Chinese PLA General Hospital. All demographic, biological, and clinical data were extracted from medical records. Relative changes of SII after two doses of ICB were defined as ΔSII% and calculated as (SIIafter 2 doses-SIIbaseline)/SIIbaseline, and so was the case for ΔNLR%. Overall survival (OS) and progression-free survival (PFS) were compared using Kaplan-Meier curves. The prognostic significance of baseline SII, NLR, and their changes was assessed in univariate and multivariate analyses using the Cox proportional hazard regression model. In total, 122 patients with PC treated with ICB were included in the present analysis. Elevated baseline SII (HR=3.28; 95% CI:1.98–5.27; P=0.03) and ΔNLR% (HR=2.21; 95% CI:1.03–4.74; P=0.04) were significantly correlated with an increased risk of death. For PC patients receiving ICB combined with chemotherapies or radiotherapies as the first-line treatment, increased baseline SII was a negative predictor for both OS (HR=8.06; 95% CI:1.71–37.86; P=0.01) and PFS (HR=2.84; 95%CI:1.37–10.38; P=0.04). Our study reveals the prognostic value of baseline SII and NLR changes in PC patients receiving ICB therapy. The clinical utility of these prognostic biomarkers needs to be further studied in prospective studies.
登录
查看更多内容
影响因子：
28.5
作者：
Long J;Lin J;Wang A;Wu L;Zheng Y;Yang X;Wan X;Xu H;Chen S;Zhao H
通讯作者：
Zhao H
影响因子：
11.5
作者：
De Giorgi, Ugo;Procopio, Giuseppe;Sternberg, Cora N.
通讯作者：
Sternberg, Cora N.
影响因子：
64.8
作者：
Mellman, Ira;Coukos, George;Dranoff, Glenn
通讯作者：
Dranoff, Glenn
影响因子：
50.3
作者：
Labelle M;Begum S;Hynes RO
通讯作者：
Hynes RO
影响因子：
8.8
作者：
通讯作者：
--